Loading clinical trials...
Loading clinical trials...
A 52 Week Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Conditions
Interventions
GSK1605786A
Placebo
+1 more
Locations
256
United States
GSK Investigational Site
Little Rock, Arizona, United States
GSK Investigational Site
Tucson, Arizona, United States
GSK Investigational Site
La Jolla, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
San Francisco, California, United States
GSK Investigational Site
Aurora, Colorado, United States
Start Date
May 9, 2011
Primary Completion Date
October 23, 2013
Completion Date
October 23, 2013
Last Updated
September 7, 2017
NCT06226883
NCT07184931
NCT06918808
NCT06647615
NCT07377188
NCT07383844
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions